The American Journal of Medicine
Volume 119, Issue 4, Supplement 1 , Pages S25-S31 , April 2006

Monitoring Osteoporosis Therapy: Bone Mineral Density, Bone Turnover Markers, or Both?

  • Sydney Lou Bonnick, MD

      Affiliations

    • Departments of Biology and Kinesiology, University of North Texas, Clinical Research Center of North Texas, Denton, Texas, USA
    • Corresponding Author InformationRequests for reprints should be addressed to Sydney Lou Bonnick, MD, Clinical Research Center of North Texas, 2921 Country Club Road, Suite 101, Denton, Texas 76210.
    • ,
  • Lee Shulman, MD

      Affiliations

    • Division of Reproductive Genetics, Department of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA

References 

  1. Rosen CJ , Hochberg MC , Bonnick SL , et al.  Fosamax Actonel Comparison Trial Investigators   Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis (a randomized double-blind study) . J Bone Miner Res . 2005;20:141–151
  2. Sebba AI , Bonnick SL , Kagan R , et al.  Fosamax Actonel Comparison Trial Investigators   Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis . Curr Med Res Opin . 2004;20:2031–2041
  3. Hodgson SF , Watts NB , Bilezikian JP , et al.  AACE Osteoporosis Task Force   American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis (2001 edition, with selected updates for 2003) . Endocr Pract . 2003;9:544–564 [published correction appears in Endocr Pract. 2004;10:90]
  4. North American Menopause Society . Management of postmenopausal osteoporosis position statement of the North American Menopause Society . Menopause . 2002;9:84–101
  5. Wasnich RD , Ross PD , Davis JW , Vogel JM . A comparison of single and multi-site BMC measurements for assessment of spine fracture probability . J Nucl Med . 1989;30:1166–1171
  6. Hui SL , Slemenda CW , Johnston CC . Baseline measurement of bone mass predicts fracture in white women . Ann Intern Med . 1989;111:355–361
  7. Melton LJ , Atkinson EJ , O’Fallon WM , Wahner HW , Riggs BL . Long-term fracture prediction by bone mineral assessed at different skeletal sites . J Bone Miner Res . 1993;8:1227–1233
  8. Cummings SR , Black DM , Nevitt MC , et al.  Study of Osteoporotic Fractures Research Group   Bone density at various sites for prediction of hip fractures . Lancet . 1993;341:72–75
  9. Marshall D , Johnell O , Wedel H . Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures . BMJ . 1996;312:1254–1259
  10. Faulkner KG . Bone matters (are density increases necessary to reduce fracture risk?) . J Bone Miner Res . 2000;15:183–187
  11. Wasnich RD , Miller PD . Antifracture efficacy of antiresorptive agents are related to changes in bone density . J Clin Endocrinol Metab . 2000;85:231–236
  12. Cummings SR , Karpf DB , Harris F , et al.   Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs . Am J Med . 2002;112:281–289
  13. Hochberg MC , Greenspan S , Wasnich RD , Miller P , Thompson DE , Ross PD . Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents . J Clin Endocrinol Metab . 2002;87:1586–1592
  14. Hochberg MC , Ross PD , Black D , et al.  Fracture Intervention Trial Research Group   Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis . Arthritis Rheum . 1999;42:1246–1254
  15. Watts NB , Cooper C , Lindsay R , et al.   Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate (greater increases in bone mineral density do not relate to greater decreases in fracture risk) . J Clin Densitom . 2004;7:255–261
  16. Chapurlat RD , Palermo L , Ramsay P , Cummings SR . Risk of fracture among women who lose bone density during treatment with alendronate (the Fracture Intervention Trial) . Osteoporos Int . 2005;16:842–848
  17. Bonnick SL , Johnston CC , Kleerekoper M , et al.   Importance of precision in bone density measurements . J Clin Densitom . 2001;4:105–110
  18. Li Z , Meredith MP , Hoseyni MS . A method to assess the proportion of treatment effect explained by a surrogate endpoint . Stat Med . 2001;20:3175–3188
  19. Shih J, Bauer DC, Orloff J, Capizzi T, Thompson D, Oppenheimer L, et al. Proportion of fracture risk reduction explained by BMD changes using Freedman analysis depends on choice of predictors . Osteoporos Int . 2002;13(suppl 3):S38–S39
  20. Melton LJ , Khosla S , Atkinson EJ , O’Fallon WM , Riggs BL . Relationship of bone turnover to bone density and fractures . J Bone Miner Res . 1997;12:1083–1091
  21. Parfitt AM . High bone turnover is intrinsically harmful (two paths to a similar conclusion. The Parfitt view) . J Bone Miner Res . 2002;17:1558–1559
  22. Riggs BL , Melton LJ . Bone turnover matters (the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density) . J Bone Miner Res . 2002;17:11–14
  23. Garnero P , Hausherr E , Chapuy MC , et al.   Markers of bone resorption predict hip fracture in elderly women (the EPIDOS Prospective Study) . J Bone Miner Res . 1996;11:1531–1538
  24. Harris ST , Watts NB , Genant HK , et al.  Vertebral Efficacy with Risedronate Therapy (VERT) Study Group   Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis (a randomized controlled trial) . JAMA . 1999;282:1344–1352
  25. Reginster J , Minne HW , Sorensen OH , et al.  Vertebral Efficacy with Risedronate Therapy (VERT) Study Group   Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis . Osteoporos Int . 2000;11:83–91
  26. Leib ES , Lewiecki EM , Binkley N , Hamdy RC . Official positions of the International Society for Clinical Densitometry . J Clin Densitom . 2004;7:1–6
  27. Writing Group for the International Society for Clinical Densitometry (ISCD) Position Development Conference . Position statement (Executive Summary) . J Clin Densitom . 2004;7:7–12
  28. Lenchik L , Kiebzak GM , Blunt BA . What is the role of serial bone mineral density measurements in patient management? . J Clin Densitom . 2002;5(suppl):S29–S38
  29. Health Care Financing Administration (HCFA) . Medicare program: Medicare coverage of and payment for bone mass measurements. Interim final rule with comment period . Fed Regist . 1998;63:34320–34328
  30. Miller PD , Baran DT , Bilezikian JP , et al.   Practical clinical application of biochemical markers of bone turnover (consensus of an expert panel) . J Clin Densitom . 1999;2:323–342
  31. National Osteoporosis Foundation. Physician’s Guide to Prevention and Treatment of Osteoporosis. Available at: http://www.nof.org/_vti_bin/shtml.dll/physguide/index.htm. Accessed May 17, 2005.
  32. NCD for Collagen Crosslinks, any method (190.19, version 1). Medicare Coverage Database. Centers for Medicare & Medicaid Services Web site; 2002. Available at: http://www.cms.hhs.gov/mdc/viewncd.asp?ncd_id=190.19&ncd_version=1&basket=ncd%3A190%3A190%2E19%3A1%3ACollagen+Crosslinks%7C%7C+any+Method). Accessed June 1, 2005.

PII: S0002-9343(05)01200-3

doi: 10.1016/j.amjmed.2005.12.020

The American Journal of Medicine
Volume 119, Issue 4, Supplement 1 , Pages S25-S31 , April 2006

Article Tools